ID Vaccine and Pasteur Merieux - Connaught Complete Licensing and Collaboration Agreement on Tuberculosis Vaccine.VANCOUVER, BC--(BUSINESS WIRE)--Oct. 2, 1995--ID BIOMEDICAL CORP. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : IDBEF IDBEF Integrated Database Extract Format VSE See DOS/VSE. VSE - Virtual Storage Extended , ME: IDB (ITS Data Bus) An interface between devices in an automobile endorsed by the Society of Automotive Engineers (SAE). Designed to fulfill the goal of Intelligent Transportation Systems (ITS), the ITS Data Bus enables engine diagnostic equipment, GPS navigation systems, )/ ID Biomedical Corporation (IDB) announced today that it and its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , ID Vaccine Corporation (IDV IDV intermittent demand ventilation. ), have entered into a license and collaboration agreement with Pasteur Merieux Serums & Vaccins S.A and Connaught Laboratories Limited (Pasteur Merieux - Connaught, a member of the Rhone-Poulenc Group), relating to IDV's tuberculosis (TB) vaccine technology. Under the agreement, Pasteur Merieux - Connaught receives a worldwide exclusive license to develop, manufacture and sell the TB vaccine. Initially, Pasteur Merieux - Connaught and IDV will collaborate in the further research and development of the TB vaccine. IDV will receive an upfront licensing fee, development support payments, and an equity investment totalling US$ 4.5 million. Additionally, IDV will receive substantial milestone and prepaid royalty payments if certain clinical and regulatory milestones are met, as well as royalties on product sales. Pasteur Merieux - Connaught will pay all expenses associated with the development and commercialisation of the TB vaccine. The common shares of IDV received by Pasteur Merieux - Connaught will in certain limited circumstances be exchangeable into common shares of IDB. IDV's TB vaccine technology was licensed from the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. (UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX ) and was invented and developed by Dr. Marcus A. Horwitz, a professor of medicine, microbiology and immunology at UCLA. Dr. Horwitz's pioneering work on intracellular pathogens and host immunity led him to the discovery that proteins secreted by intracellular organisms allow the immune system to recognise and destroy intracellular pathogens. This discovery is supported by studies done with two intracellular organisms Legionella pneumophila and Mycobacterium tuberculosis. Animal studies under Dr. Horwitz's direction have demonstrated the potential to develop a vaccine that will induce protective immunity against tuberculosis. Use of the experimental vaccine protected these animals against death, clinical illness (including weight loss), and growth of the disease organism in the lungs and elsewhere in the body. Additional studies in primates have demonstrated that the vaccine caused no local or systemic toxicity and elicited cell mediated immunity, a prerequisite for protective immunity against TB. Tuberculosis is the world's leading cause of illness and death from an infectious disease and is expected to cause 300 million new infections and 30 million deaths in the next decade according to a recently released WHO Report entitled "WHO Report on the Tuberculosis Epidemic, 1995". Tuberculosis has made a dramatic comeback after years of decline in industrialised Adj. 1. industrialised - made industrial; converted to industrialism; "industrialized areas" industrialized industrial - having highly developed industries; "the industrial revolution"; "an industrial nation" countries because of the HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. epidemic, immigration immigration, entrance of a person (an alien) into a new country for the purpose of establishing permanent residence. Motives for immigration, like those for migration generally, are often economic, although religious or political factors may be very important. , travel, the ageing of populations and decreased vigilance by public health authorities. "The development of an effective TB vaccine is an important goal for Pasteur Merieux - Connaught, not only because it represents a large commercial market opportunity but also because of our commitment to disease prevention and control worldwide," said Mr. Jean Jacques Bertrand, President of Pasteur Merieux - Connaught. "We are pleased to be working with IDV to develop an effective TB vaccine and we believe that the approach of using extracellular proteins as the immunising agent offers the best opportunity for developing a safe and effective subunit vaccine against tuberculosis." "IDV is extremely pleased to be collaborating with a company of the stature of Pasteur Merieux - Connaught," stated Todd Patrick, Vice President, Business Development of IDV. "Pasteur Merieux - Connaught has the necessary resources and expertise to take the TB vaccine through clinical trials and to product sales on a worldwide basis. This agreement also exemplifies our business strategy of getting involved early in the research and development cycle and then partnering for the regulatory approval, manufacturing and marketing of our vaccine products." Dr. Anthony Holler, Medical Director of IDV said "TB is one of the deadliest diseases in the world today and the development of an effective TB vaccine is urgently needed. This agreement with Pasteur Merieux - Connaught brings our vaccine a step closer to preventing this disease". Pasteur Merieux Serums & Vaccins S.A., a 100 percent owned Rhone-Poulenc company, is a world leader in the development and marketing of vaccine products. Through its subsidiary company, Connaught Laboratories Limited (headquartered in Toronto, Canada), Pasteur Merieux Serums & Vaccins S.A. has a large research, development and manufacturing presence in North America. Connaught Laboratories Limited is Canada's largest fully integrated biotechnology company and North America's leading manufacturer of vaccines. Pasteur Merieux - Connaught's purpose is to contribute, as a global leader, to the protection and maintenance of human health by creating superior immunological products for the prevention of infectious diseases and cancers. ID Vaccine is a U.S. based company engaged in the development of subunit vaccine and immunotherapeutic products for human infectious diseases. IDV's parent, ID Biomedical, is a Canadian biotechnology company which is developing a nucleic acid diagnostic system and related products based on its proprietary Scissile scis·sile adj. Cut or split easily: a scissile mineral; a scissile peptide bond. [French, from Latin scissilis, from scissus, past participle of Linkage Technology and Cycling Probe Technology  This article or section is in need of attention from an expert on the subject.Please help recruit one or [ improve this article] yourself. See the talk page for details. . -0- NOTE: Neither NASDAQ, The Montreal Exchange nor The Vancouver Stock Exchange Vancouver Stock Exchange (VSE) A securities and options exchange in Vancouver, British Columbia, (Canada), specializing in venture capital companies. Vancouver Stock Exchange See Canadian Venture Exchange (CDNX). has approved or disapproved of the information contained herein. CONTACT: Anthony Holler Medical Director ID Vaccine Corporation 604/431-9314 or Hugh Notman Director, Corporate Communications ID Biomedical Corporation 604/431-9314 or Don McKibbin Director of Public Affairs Connaught Laboratories Limited 416/667-2694 or Beatrice Dubosq-Mathieu Corporate Communications Pasteur Marieux - Connaught Lyon, France (33) 72 73 77 55 Frank HollerPresident & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion